Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Dr. Miyake joined AVM (Astellas Venture Management) in August 2023 and is currently in charge of investment opportunities in Ophthalmology, Neurology, Gene therapy, and Cell Therapy. Prior to AVM, he was responsible for searching and evaluating partnering and collaboration opportunities in Immunology, Immuno-oncology, Ophthalmology, Otology, Monogenic Disorders, Neurology, and Psychiatry in Astellas Innovation Management and Business Development over the past 3.5 years.
Dr. Miyake holds a Ph.D. in Neuroscience from the medical school of Osaka University and had postdoc training as a visiting fellow at the stroke branch in NINDS/ NIH. After joining Astellas, he led modality-based drug discovery research (small molecules, cell, and gene therapy) and the team for 16 years as a molecular pharmacologist at Astellas Research Institute of America (ARIA) in San Diego/Chicago and Astellas Pharma Inc. in Japan.
Dr. Miyake received his MBA from GLOBIS University in March 2025.
